Skip to Content
Merck
CN

SML4043

PCI-24781

≥98% (HPLC)

Synonym(s):

3-[(Dimethylamino)methyl]-N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide, 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Abexinostat, CRA-024781

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C21H23N3O5
CAS Number:
Molecular Weight:
397.42
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to pink

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

SMILES string

N(O)C(=O)c1ccc(cc1)OCCNC(=O)c2[o]c3c(c2CN(C)C)cccc3
CN(C)CC1=C(C(NCCOC2=CC=C(C(NO)=O)C=C2)=O)OC3=CC=CC=C31

InChI

1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)

InChI key

MAUCONCHVWBMHK-UHFFFAOYSA-N

Biochem/physiol Actions

Orally bioavailable, potent and selective pan-HDAC inhibitor.
PCI-24781 (Abexinostat) is an orally bioavailable, potent, and selective pan-HDAC inhibitor that exhibits potent antitumor activities. It inhibits all Class I and Class II HDAC isoforms (Ki = 7 nM HDAC1, 19 nM HDAC2, 8.2 nM HDAC3/SMRT, 17 nM HDAC6, 280 nM HDAC8, 24 nM HDAC10) although it is reported to be a more potent inhibitor of HDACs 1 and 3 at low concentrations.

Storage Class Code

11 - Combustible Solids

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sofia Rivera et al.
Oncotarget, 8(34), 56210-56227 (2017-09-17)
Despite prominent role of radiotherapy in lung cancer management, there is an urgent need for strategies increasing therapeutic efficacy. Reversible epigenetic changes are promising targets for combination strategies using HDAC inhibitors (HDACi). Here we evaluated on two NSCLC cell lines
Tianshu Yang et al.
Theranostics, 11(5), 2058-2076 (2021-01-28)
Histone deacetylases (HDACs) are involved in key cellular processes and have been implicated in cancer. As such, compounds that target HDACs or drugs that target epigenetic markers may be potential candidates for cancer therapy. This study was therefore aimed to
Joseph J Buggy et al.
Molecular cancer therapeutics, 5(5), 1309-1317 (2006-05-30)
CRA-024781 is a novel, broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials for cancer. CRA-024781 inhibited pure recombinant HDAC1 with

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service